Literature DB >> 17765480

Remission in schizophrenia: applying recent consensus criteria to refine the concept.

Robert A Lasser1, Henry Nasrallah, Lars Helldin, Joseph Peuskens, John Kane, John Docherty, Anselmo Toledo Tronco.   

Abstract

Although the concept of remission has been widely accepted and utilized in depression and anxiety disorders, there has been much less emphasis on defining remission in schizophrenia. Recently, an expert consensus definition of remission in schizophrenia was proposed along specific operational criteria for the attainment of remission focusing on the three core dimensions of psychopathology identified within schizophrenia: psychoticism, disorganization and negative symptoms. To date, the criteria have been applied retrospectively to several clinical studies, and these have demonstrated that the proposed definition of remission correlates significantly with established measures of symptom severity, functioning and quality of life, and appears achievable for a significant proportion of patients receiving at least 3 months of pharmacotherapy. In this article we extend the notion of remission to include an examination of the possible association of several modifiable and unmodifiable factors and co-morbidities on remission status. We also propose an investigation into the likelihood of different patient populations in achieving remission as well as assessing the impact of remission on health care costs and family burden. Since cognitive dysfunction and negative symptoms may be strongly correlated with a lower likelihood of achieving remission, we recommend retrospective and/or prospective studies to determine the relationship between neurocognitive status and the predominance of negative symptoms at treatment start and the probability of achieving remission. Taken together, these studies should help identify key predictors of remission, further define the remitted state, reduce therapeutic pessimism, raise treatment expectations and chart a strategy for further research in this important area.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17765480     DOI: 10.1016/j.schres.2007.05.003

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  12 in total

1.  Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years.

Authors:  Clifford M Cassidy; Ross Norman; Rahul Manchanda; Norbert Schmitz; Ashok Malla
Journal:  Schizophr Bull       Date:  2009-03-25       Impact factor: 9.306

Review 2.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

Review 3.  Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis.

Authors:  Mario Alvarez-Jiménez; Alexandra G Parker; Sarah E Hetrick; Patrick D McGorry; John F Gleeson
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 4.  Neurocognition: clinical and functional outcomes in schizophrenia.

Authors:  Martin Lepage; Michael Bodnar; Christopher R Bowie
Journal:  Can J Psychiatry       Date:  2014-01       Impact factor: 4.356

5.  Symptomatic Remission in Schizophrenia and its Relationship with Functional Outcome Measures in Indian Population.

Authors:  Selvaraj Madhivanan; Komal Jayaraman; Sharon Joe Daniel; Jeyaprakash Ramasamy
Journal:  J Clin Diagn Res       Date:  2017-01-01

6.  Remission and recovery during the first outpatient year of the early course of schizophrenia.

Authors:  Joseph Ventura; Kenneth L Subotnik; Lisa H Guzik; Gerhard S Hellemann; Michael J Gitlin; Rachel C Wood; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2011-07-18       Impact factor: 4.939

7.  Smoking processes, panic, and depressive symptoms among treatment-seeking smokers.

Authors:  Dawn W Foster; Kirsten J Langdon; Norman B Schmidt; Michael Zvolensky
Journal:  Subst Use Misuse       Date:  2014-12-15       Impact factor: 2.164

Review 8.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

9.  Neuropsychological correlates of remission in chronic schizophrenia subjects: The role of general and task-specific executive processes.

Authors:  Thais Rabanea-Souza; Henrique T Akiba; Arthur A Berberian; Rodrigo A Bressan; Álvaro M Dias; Acioly L T Lacerda
Journal:  Schizophr Res Cogn       Date:  2016-02-16

10.  Study on psychoeducation enhancing results of adherence in patients with schizophrenia (SPERA-S): study protocol for a randomized controlled trial.

Authors:  Donatella Rita Petretto; Antonio Preti; Carlo Zuddas; Franco Veltro; Marco Bruno Luigi Rocchi; Davide Sisti; Valentina Martinelli; Mauro Giovanni Carta; Carmelo Masala
Journal:  Trials       Date:  2013-10-07       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.